Sarepta Therapeutics (SRPT) Tops Q3 EPS by 29c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Citi agrees to acquire rewards platform Kard Financial
- Total darkness, then sunset as full eclipse wows spectators in Spain
- Burry doubles down on Nebius short after stock surges 34% on earnings
Sarepta Therapeutics Announces Third Quarter 2020 Financial Results and Recent Corporate Developments
November 5, 2020 4:05 PM ESTNet product sales of $121.4 million, a 23% increase over same quarter of prior year
CAMBRIDGE, Mass., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ: SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the third quarter of 2020.
Even as the pandemic created challenges throughout the third quarter, I am pleased to report that the Sarepta team was able to continue to serve the Duchenne muscular dystrophy community with little interruption, achieving net product revenue of $121.4 million for EXONDYS 51 (eteplirsen) and VYONDYS 53... More
